Abstract: The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.
Type:
Grant
Filed:
April 25, 2013
Date of Patent:
April 26, 2016
Assignees:
KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, HANDOK PHARMACEUTICALS CO., LTD.
Inventors:
Jin Hee Ahn, H. S. Pagire, Sang Dal Rhee, Ki Young Kim, Won Hoon Jung, Myung-Ae Bae, Jin Sook Song, Kwang-Rok Kim, Hyun Jung Kwak
Abstract: The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.
Type:
Application
Filed:
October 19, 2011
Publication date:
August 22, 2013
Applicant:
HANDOK PHARMACEUTICALS CO., LTD.
Inventors:
Young Gyu Cho, Hye Jeong Shin, Woon Young Lee, Woo Ick Jang